6,980 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Headlands Technologies LLC

Headlands Technologies LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 6,980 shares of the biopharmaceutical company’s stock, valued at approximately $124,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Principal Financial Group Inc. grew its position in TG Therapeutics by 3.9% during the 1st quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 1,322 shares during the last quarter. Swiss National Bank grew its position in TG Therapeutics by 0.5% during the 1st quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock worth $4,321,000 after purchasing an additional 1,500 shares during the last quarter. nVerses Capital LLC grew its position in TG Therapeutics by 34.9% during the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 1,500 shares during the last quarter. Arizona State Retirement System grew its position in TG Therapeutics by 3.9% during the 2nd quarter. Arizona State Retirement System now owns 41,069 shares of the biopharmaceutical company’s stock worth $731,000 after purchasing an additional 1,539 shares during the last quarter. Finally, Pingora Partners LLC purchased a new position in TG Therapeutics during the 4th quarter worth $27,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Up 2.3 %

Shares of NASDAQ:TGTX opened at $23.73 on Monday. The company has a market cap of $3.67 billion, a price-to-earnings ratio of 103.17 and a beta of 2.21. The firm’s 50-day simple moving average is $21.63 and its 200-day simple moving average is $18.09. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. TG Therapeutics, Inc. has a fifty-two week low of $6.46 and a fifty-two week high of $25.70.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. During the same quarter last year, the business earned ($0.34) earnings per share. The business’s revenue for the quarter was up 357.0% compared to the same quarter last year. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on TGTX shares. HC Wainwright reissued a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a research report on Tuesday, August 6th. The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.83.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.